Invesco Biotechnology & Genome ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Invesco Biotechnology & Genome ETF PBE
Morningstar’s Analysis PBE
Will PBE outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 45.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Vertex Pharmaceuticals Inc | 4.98 | 14M | Healthcare |
Amgen Inc | 4.94 | 14M | Healthcare |
Royalty Pharma PLC Class A | 4.85 | 14M | Healthcare |
Biogen Inc | 4.83 | 14M | Healthcare |
Regeneron Pharmaceuticals Inc | 4.78 | 14M | Healthcare |
CareDx Inc | 4.56 | 13M | Healthcare |
Gilead Sciences Inc | 4.55 | 13M | Healthcare |
Alnylam Pharmaceuticals Inc | 4.28 | 12M | Healthcare |
United Therapeutics Corp | 4.08 | 12M | Healthcare |
Bio-Techne Corp | 3.64 | 10M | Healthcare |